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Summary Sentence: Prostaglandin E2 produced by inflammatory monocytes inhibit skin TRM 
function and antigen-specific immunity in older adults.  
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Abbreviations: 
CBA – cytometric bead array 
CRP - C reactive protein 
COX2 – Cyclooxygenase 2 
DC – Dendritic Cell 
EP4 - Prostaglandin E2 receptor 4 
LPS – Lipopolysaccharide 
ILT - Immunoglobulin-like transcript 
p38-MAPK - p38 mitogen-activated protein kinase 
PD-L - Programme-death ligand 
PGE2 - Prostaglandin E2 
PV – perivascular infiltrate 
SASP - senescence associated secretory phenotype 
TAF - telomere-associated DNA-damage  
Tregs - T regulatory cells  
TRM - T resident-memory cells  
VZV - Varicella Zoster Virus  
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Abstract: 
We have previously shown that healthy older adults exhibit reduced cutaneous immune 
responses during a varicella zoster virus (VZV) antigen challenge that correlated with a non-
specific inflammatory response to the injection itself.  
Here we found that needle damage during intradermal injections in older adults led to an 
increase in the number of cutaneous senescent fibroblasts expressing CCL2, resulting in the 
local recruitment of inflammatory monocytes. These infiltrating monocytes secreted 
prostaglandin E2 (PGE2) that inhibited resident memory T cell (TRM) activation and 
proliferation. Pre-treatment of older subjects with a p38-MAPK inhibitor in vivo decreased 
CCL2 expression and inhibited monocyte recruitment and secretion of PGE2. This coincided 
with an increased response to VZV antigen challenge in the skin.  
Our results point to a series of molecular and cellular mechanisms that link cellular 
senescence, tissue damage, excessive inflammation and reduced immune responsiveness 
in human skin and demonstrate that tissue-specific immunity can be restored in older adults 
by the short-term inhibition of inflammatory responses.  
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Introduction: 
Immunity decreases during ageing as demonstrated by the increased susceptibility to 
infections including pneumonia and influenza, re-activation of latent infections such as 
varicella zoster virus (VZV), decreased vaccine efficacy and increased incidence of cancer1, 
2, 3. In addition, there is an increase in low grade systemic inflammation in older humans 
termed inflammageing, that is characterised by high serum levels of the inflammatory 
cytokines IL-6, IL-1β, TNFα and C reactive protein (CRP)4. This elevated expression of 
inflammatory proteins is a strong predictor for frailty and mortality5, 6. Mechanisms that 
contribute to inflammageing are multifactorial, and include increased numbers of senescent 
cells (which secrete many inflammatory proteins as part of the senescence associated 
secretory phenotype (SASP), increased gut permeability and subsequent lipopolysaccharide 
(LPS; a TLR4 ligand) exposure, expression of damage-associated molecular pattern 
molecules (DAMPs) and failure of immune resolution7.   
Cutaneous recall antigen challenge is often used as a measure of effective immunity. Older 
individuals have reduced responses to challenge with various recall antigens including 
tuberculin PPD, Candida albicans and varicella zoster virus (VZV) antigens 8, 9, 10, 11. We 
showed previously that this decrease was a result of heightened inflammatory responses in 
the skin of older individuals during immune challenge and not from changes in antigen-
specific circulating or skin resident-memory T cells (TRM)12. However, the mechanism by 
which inflammation inhibits antigen-specific immunity in the skin is unknown.  
Here we show that when challenging old individuals in the skin with VZV antigens, the tissue 
damage caused by the injection of the VZV antigen itself induces senescent fibroblasts to 
recruit CCR2+CD14+ monocytes from the circulation. These infiltrating monocytes express 
cyclooxygenase 2 (COX2) and produce prostaglandin E2 (PGE2) that inhibits TRM activation 
and proliferation. Pre-treatment of older individuals with and oral p38 MAPK inhibitor 
inhibited monocyte recruitment and PGE2 production during the immune response to VZV. 
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This resulted in a significantly enhanced VZV-specific mediated delayed type 
hypersensitivity responses associated with the activation and expansion of T cell numbers in 
the skin. These data identify a broad mechanism by which even mild tissue damage may 
induce inflammation in the tissues of older individuals that can inhibit immunity. An important 
consideration is whether the short-term blockade of inflammation would enhance the 
immune responses of older humans at early stages of (pathogen) infection where the 
infectious agent may induce damage and excessive inflammation that may retard 
subsequent immune responsiveness.   
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Results: 
Inappropriate response to tissue damage in the skin during ageing 
Old (≥65 years) and young (<40 years) individuals were recruited for this study, donor 
characteristics can be found in Supplementary Table 1. Although there were more females in 
the older adult group, there was no difference in response between the different genders 
within this group (Extended Figure 1A). Volunteers were injected intradermally with VZV skin 
test antigen in one arm (for the clinical score) and with saline (0.9% NaCl) in the other arm 
as a control. 5mm biopsies were collected from the injection sites 6 hours post-injection and 
compared to biopsies of normal (unmanipulated) skin (Figure 1A). The VZV injection site 
was assessed for clinical score 72 hours after injection and the induration, palpability and 
change in erythema from baseline were measured and scored, as described before11. We 
showed previously that mononuclear phagocyte numbers were increased at the site of saline 
injection in old but not young subjects and that this accumulation negatively correlated with 
the magnitude of antigen-specific responses induced in the contralateral arm of the same 
individual9. Multiparametric flow cytometry on disaggregated skin biopsies from old donors 
showed no change in the number of CD11c+, CD1c+ or BDCA-3+ dendritic cells (DC) in 
response to saline challenge (Extended Data Figure 2A-D). Neutrophils, as determine by 
CD66b expression by immunofluorescence or CD45+lineage-CD16+HLA-DR- by flow 
cytometry were observed at very low numbers in normal skin which did not significantly 
change after saline injection (Extended Data Figure 3A and B and 4A and B). These data 
implies that the increase in mononuclear phagocytes was due to accumulation of 
monocytes. 
To enumerate the changes in monocyte numbers following saline injection we assessed 
paired samples and expressed data as delta change from normal skin. This was to mitigate 
against inter-personal variation in the magnitude of responses observed (Extended Data 
Figure 4A). CD14 was used to identify monocytes in these experiments as it is expressed by 
the majority of peripheral blood monocytes (classical and intermediate) while CD16+CD14- 
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monocytes were relatively rare in the skin (Extended Data Figure 5A). There was a 
significant increase in CD14+ cells in saline injected skin at 6 hours post-injection (Figure 1B 
and 1C). We next investigated the expression of CCR2, a chemokine receptor for CCL2, 
which is highly expressed by CD14+ monocytes13, 14. There was a significant increase in 
number of CD14+CCR2+ cells in saline injected skin as compared to normal skin in old but 
not young subjects (Figure 1C, larger images can be seen in Supplementary Figure 1A and 
B). This response to saline was transient as by 24 hours post-injection similar frequency 
frequencies of monocytes were detected in normal and saline-injected skin (Extended Data  
Figure 4B). Multiparametric flow cytometry analysis of normal and saline biopsies, using the 
gating strategy shown in Extended Data Figure 5A, confirmed that there was a significant 
increase in CD14+ and CCR2+CD14+ cells in old saline-injected skin (Figure 1D). We also 
observed a smaller population of HLA-DR+ cells that were CCR2+CD14- in normal skin, 
however this population did not significantly change after saline injection (Extended Data 
Figure 5C). Further phenotyping of the HLA-DR+ population with CD86, CLA, SLAN, CD16, 
CX3CR1 showed that their expression was similar before and after saline injections. The 
only population that changed in the old subjects after saline-injection were those that 
expressed CD14 and CCR2, suggesting that it was an increase in the number of 
CD14+CCR2+ monocytes rather than a change in their phenotype (Extended Data Figure 
5D-F).  
To investigate whether this inflammatory response after saline injection in older humans was 
due to injection with sodium chloride itself or a response to needle injury, we performed 
intradermal injections with the same volume of air instead of saline (20μl). Air injection also 
induced a significant increase in the number of monocytes at the site of challenge in old but 
not young adults compared to normal skin (Extended Data Figure 4C). The accumulation of 
monocytes was also observed at six hours at the site of VZV injection in old but not young 
adults (Figure 1E). Taken together these data suggest that old subjects have a heightened 
inflammatory response to mild skin injury that is not observed in young individuals.  
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We previously showed that >85% of older individuals have a low VZV response (clinical 
score between 0-3), while >85% of young individuals have a score of between 3-108, 12. 
However, a small proportion of older people (~15%) show good cutaneous VZV 
responsiveness (score above 3), a group we designated as ‘old responders’. To assess 
whether the CD14+ monocyte infiltration was a characteristic of all aged individuals or only 
those with reduced VZV-specific immunity, we investigated the accumulation of these cells 
after saline in old VZV responders (red circles) and low responders (filled circles; Fig1F). An 
increase in monocytes at the site of challenge was only observed in old individuals with a 
low clinical score while old individuals with a good clinical score behaved similarly to young 
individuals with low monocyte infiltration. Taken together, there was a significant negative 
correlation between the fold change in CD14+ monocytes in response to saline challenge 
and the VZV clinical score (R=-0.38 and p=0.04; Figure 1E), a similar correlation was 
observed between CD14+CCR2+ cells and the clinical score (Supplementary Figure 2).  
Collectively this indicates that the early recruitment of monocytes to the site of skin challenge 
in old people was associated with decreased antigen-specific immunity. 
 
Senescent stromal cells contribute to recruitment of monocytes in the old. 
We hypothesised that the increase in CD14+ cells in the skin was due to recruitment of 
circulating monocytes, since CCR2+ expression supported the possibility of recruitment in 
response to CCL2. The alternative explanation that this was a consequence of the 
proliferation of local tissue-resident macrophages (identified as CD163+), however this was 
not observed (Extended Data Figure 6A-C). This is in line with murine studies showing 
dermal macrophages are constantly replenished from the monocyte pool rather than 
proliferation15. We first investigated the activation status of the dermal endothelium to 
determine whether it was permissive for monocyte recruitment. CD62E, also known as E-
selectin, was used as a marker of activated endothelium as it binds to sialylated 
carbohydrates expressed on leukocytes and facilitates their extravasation into the tissue.  
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Saline-injected skin of old but not young adults exhibited increased CD62E expression on 
the CD31+ endothelium when compared to normal skin (Figure 2A and B). Furthermore, 
transcriptional analysis of skin biopsies indicated that there was increased expression of a 
range of genes encoding monocyte chemoattractants including CCL2 (one of the main 
monocyte chemoattractants), CXCL10, CXCL2 and CXCL1 in old but not young in response 
to saline injection (Figure 2C). Increased CCL2 expression in saline-injected old skin was 
confirmed by immunofluorescence staining of skin sections (Figure 2D). As expected, there 
was no significant change in the expression of CCL2 cells in young skin after saline-injection 
(Figure 2D). 
We next examined the source of monocyte chemoattractants and found that resident 
mononuclear phagocytes were not the main source of CCL2 (Supplementary Figure 9A and 
B). Using FSP-1 as a marker of fibroblasts, we found that there was a significant increase in 
the number of fibroblasts expressing CCL2 in the skin of old subjects after saline injection as 
compared to normal un-injected skin (Figure 2E and F, larger images can be seen in 
Supplementary Figure 9C). It is known that fibroblasts can produce CCL216. We and others 
have shown that there are increased numbers of senescent fibroblasts in the skin of older 
humans16, 17, 18 and CCL2 is a known component of the senescence associated secretory 
phenotype (SASP)19. Indeed, using p16 as a marker of senescence we found that 
FSP1+p16+ fibroblasts were the main source of CCL2 after saline injection of old donors 
(Figure 2G and H). Senescent fibroblasts made up 54.1% of CCL2+FSP1+ cells in normal 
skin which increased to 66.8% in saline-injected skin (Supplementary Figure 9E). Although 
some non-senescent fibroblast evidently expressed CCL2, our previous data showed that 
senescent fibroblasts produce significantly more CCL2 than the non-senescent fibroblasts16. 
Therefore, the early production of SASP-related mediators by senescent fibroblasts after 
saline injection (including CCL2) may lead to the recruitment of inflammatory monocytes to 
the site of skin challenge. This interaction between senescent cells and monocyte 
recruitment is supported indirectly by the significant correlation between the number of 
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senescent fibroblasts present in the skin, as determined by telomere-associated DNA-
damage (TAF) foci positive FSP-1+ cells (representative staining can be found in Extended 
Data Figure 8),  present in the skin and the extent of CD14+ monocyte infiltration after saline 
injection (Fig. 2I, larger images can be seen in Supplementary Figure 9D). 
 
Monocytes inhibit TRM proliferation through production of Prostaglandin E2. 
We next investigated the mechanisms by which the recruitment of monocytes reduced 
antigen-specific immunity in old subjects. We first assessed inhibitory pathways in normal 
and saline injected skin by RNAseq. We found that saline injection in old individuals 
increased the expression of a number of immunoglobulin-like transcript (ILT) receptors such 
as LILRB3 (ILT5), LILRB2 (ILT4), LILRA2 (ILT1), LILRB4 (ILT3) and LILRB1 (ILT2), 
inhibitory ligands such as CD274 (programme-death ligand 1; PDL-1) and PDCD1LG2 (PDL-
2), ligand for the T cell receptor TIGIT and PVR, as well as inducible COX2 enzyme 
(PTGS2) (Figure 3A).   
PTGS2 (encoding COX2) was one of the most highly upregulated genes in saline-injected 
skin of the old subjects9 and elevated COX2 expression following saline injection was 
confirmed at the protein level by immunohistology (Figure 3B and C, larger images can be 
seen in Extended Data Figure 9A). When staining for COX2 was performed in combination 
with CD14 there was a significant increase in CD14+COX2+ cells in saline injected as 
compared to normal skin (Figures 3D). There was no significant difference in the number of 
CD14-COX2+ cells (Extended Data Figure 9B), indicating that this increase in COX2 was 
specific to CD14+ monocytes. 
To demonstrate that COX2 expressing monocytes can inhibit the activation of CD4+ T cells, 
we first induced COX2 expression in monocytes isolated from peripheral blood by 
stimulation with LPS (1ng/ml) for 3 hours.  LPS treatment significantly increased COX2 
expression as compared to untreated controls (Supplementary Figure 3)20, 21. Unstimulated 
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and LPS-stimulated monocytes were then co-cultured with autologous peripheral CD4+ T 
cells in the presence of anti-CD3 and IL-2 and proliferation was assessed after four days. 
Stimulated monocytes inhibited CD4+ T cell proliferation as compared to control 
(unstimulated) monocytes (Figure 3E-F). However, production of the cytokines IFNy, IL-2 
and IL-10 was not affected at day 4 post-culture. The COX2-specific inhibitor NS-398 was 
then used to determine if COX2 expression was involved in the inhibition of CD4+ T cell 
proliferation. Treatment with NS-398 led to a significant increase in the proliferation of the 
CD4+ T cells (Figure 3G and H and Supplementary Figure 4A). COX2 is involved in the 
production of a range of lipid mediators, the most common being PGE222. To establish if 
PGE2 was involved in the inhibition of CD4+ T cell proliferation, we blocked the receptor for 
PGE2, EP4, on CD4+ T cells using the inhibitor MF-498. Blockade of PGE2 signalling also 
significantly increased the proliferation of the CD4+ T cells in the presence of inflammatory 
monocytes (Figure 3H and I and Supplementary Figure 4B). To confirm that PGE2 did not 
alter the monocyte phenotype we cultured monocytes with PGE2 and assessed their 
inhibitory receptor (CD112, CD155, Galectin 9, ILT3 and PDL-1, PDL-2) expression and 
cytokine production. We did not observe any significant effects of PGE2 treatment on the 
expression of these receptor in monocytes, confirming that PGE2 directly affected CD4+ T 
cells. To assess if the above observations were relevant in the skin of old donors in vivo, we 
investigated Prostaglandin E2 receptor 4 (EP4) expression by skin-resident CD4+CD69+ TRM 
cells in older volunteers. (Figure 4A). The majority of CD4+ TRM expressed EP4 (81.2%), 
indicating that they have the capacity to respond to PGE2 produced by monocytes. We next 
assessed the co-localisation of CD14+ monocytes and CD4+TRM cells in normal and saline 
injected skin from old subjects. In normal skin, CD14+ monocytes were on average 15.86μm 
away from CD4+ TRM, however after saline injection the monocytes were significantly closer 
to the CD4+ TRM (9.47μm; Figure 4B and C). This increased proximity was likely due to 
increase in the number of monocytes in the skin after saline injection. To confirm that 
monocytes have the ability to suppress skin CD4+ TRM proliferation, CD4+ TRM were isolated 
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from the skin using suction blister technology as described previously (Figure 4D)11. Skin 
CD4+ TRM cells were then pre-labelled with CellTrace Violet and stimulated with CD3 and IL-
2 in the presence of either stimulated or unstimulated monocytes for four days. We observed 
a significant reduction in CD4+ TRM cell proliferation in the presence of stimulated as 
compared to unstimulated monocytes (Figure 4E and F) supporting the hypothesis that 
COX2+ monocytes have the capability to suppress TRM proliferation.  
 
p38 MAP kinase inhibition significantly reduces CCL2 production from senescent 
fibroblasts. 
We showed previously that treatment of old subjects with the anti-inflammatory p38-MAPK 
inhibitor, Losmapimod, significantly enhanced the response to VZV antigens in the skin9. To 
investigate if p38-MAPK inhibition altered CCL2 production and inflammatory monocyte 
recruitment in the skin, RNAseq analysis was performed on biopsies collected from normal 
skin and from skin 6 hours after saline injection with saline both before and after 
Losmapimod treatment (study design Figure 5A). We stratified our subjects in the RNAseq 
analysis according to the extent of clinical score improvement. The individuals that had no 
improvement in clinical score are represented as white, and those who had the biggest 
improvement in clinical score after Losmapimod treatment represented by dark green 
(Figure 5B). A list of all differentially expressed genes can be found in Supplementary Table 
4. Saline injection resulted in a large pro-inflammatory response with a significant increase in 
the expression of inflammatory associated genes such as CCL2, CAFCL8, FOSL1, IL1B and 
TREM1 at 6 hours pre-Losmapimod treatment (Figure 5C). This response to saline was 
reduced after Losmapimod pre-treatment (Figure 5C) and of the top six significantly 
upregulated genes in saline-injected skin as compared to normal were no longer significantly 
different post-Losmapimod treatment (Extended Data Figure 10A).  In addition, there was a 
strong trend towards reduction in saline-specific gene expression after Losmapimod 
treatment (p=0.06; Supplementary Figure 14B).  RNAseq analysis showed that the 
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expression of monocyte chemoattractants (induced in response to saline injection) was 
reduced post-Losmapimod treatment (Extended Data Figure 10E). However, the reduction in 
genes specific to saline response in old (saline-specific gene expression) did not correlate 
with improvement in clinical score (Extended Data Figure 10C) and the same was observed 
with CCL2 (Extended Data Figure 10D).  
After Losmapimod treatment there was a significant reduction in the number of CCL2+ cells 
and the number of CCL2+ senescent (p16+FSP-1+) fibroblasts (Figures 5D, 5E). Treatment of 
senescent dermal fibroblasts with Losmapimod in vitro significantly reduced their CCL2 
production, suggesting Losmapimod could have a direct effect on senescent fibroblast in 
vivo (Extended Data Figure 10F). As a result of the reduced CCL2 production, monocyte 
infiltration in saline injected skin was significantly decreased post-Losmapimod treatment 
(Figure 5F). A significant reduction in the number of monocytes after Losmapimod treatment 
was observed when VZV injected skin (6 hour post-injection) was assessed (Figure 5G). 
Together, these data indicate that p38-MAPK inhibition significantly reduces CCL2 
production from senescent fibroblasts reducing the accumulation of monocytes at sites of 
saline or VZV antigen challenge in the skin.  
 
p38 MAP kinase inhibition significantly inhibits PGE2 that restores T cell proliferation. 
COX2 expression has been shown to be regulated downstream of p38-MAPK signalling20, 23, 
implying that Losmapimod may act by inhibiting COX2 expression in vivo. To test this, we 
performed Western blot analysis of LPS activated monocytes in the presence or absence of 
Losmapimod. Losmapimod significantly decreased the LPS induced expression of phopho-
p38 MAPK and COX2 in vitro (Figures 6A and B). In addition, PGE2 production was also 
significantly decreased after Losmapimod treatment (Figure 6C).  Furthermore, the addition 
of Losmapimod to co-cultures of CD4+ T cells that were stimulated in the presence of LPS 
treated monocytes (Figure 6D and E) enhanced their proliferation to a similar extent to that 
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observed after direct COX2 or EP4 inhibition (Figure 3G and H). In line with these 
observations, the increase in CD14+COX2+ cells after saline injection was also inhibited after 
post-Losmapimod treatment in vivo (Figure 6F). These data collectively suggest that in vivo 
Losmapimod can restore CD4+ T cell responses in part through the inhibition of COX2 
expression. 
 
p38 MAP kinase inhibition significantly increases T cell infiltration into the site of VZV 
challenge. 
We assessed the clinical score of 42 old subjects after VZV antigen challenge both before 
and after Losmapimod treatment. We confirmed and extended our previous observations 
that treatment with Losmapimod significantly increased VZV clinical score (n=42; Figure 7A). 
No difference was observed between male and female volunteers in their response to 
Losmapimod treatment (Extended Data Figure 1B). Losmapimod treatment also significantly 
decreased serum CRP in all individuals, irrespective of whether they showed an improved 
skin response to VZV challenge (Figure 7B).  
We previously identified a significant association between the clinical score after VZV 
antigen challenge and the accumulation of T cells and DCs at the site of injection8, 9. VZV 
challenged skin sections collected pre- and post-Losmapimod were stained for CD4 or CD8, 
Ki67 and CD11c (Figure 7C and D). We found that Losmapimod pre-treatment was 
associated with a significant increase in CD4+ (Figure 7E) and CD8+ (Figure 7G) T cell 
accumulation in the skin 7 days after VZV injection. The increased number of CD4+ and 
CD8+ T cells in perivascular infiltrates was associated with an increased proliferation of 
these cells in situ indicated by Ki67 expression (Figures 7F and H)12. Concurrently there was 
also an increase in CD11c+ DCs in the VZV-injected skin post-Losmapimod (Figure 7I), 
suggesting there was an increase in T cell and DC clusters as observed previously9. Taken 
together our data show that short-term blockade of inflammation using the p38 MAP kinase 
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inhibitor Losmapimod can significantly enhance the cutaneous immune response to antigen 
challenge in older adults.  
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Discussion: 
We demonstrate that senescent fibroblasts in the skin of old subjects secrete an array of 
chemokines including CCL2 in response to tissue injury, such as that induced by injecting 
saline, VZV or air. This leads to recruitment of inflammatory monocytes into the skin that 
inhibit skin TRM activation in part by secreting lipid mediators such as PGE2 via a COX2-
dependant pathway. However, short-term systemic p38-MAPK blockade (that also inhibits 
COX2) leads to a significant reduction in CCL2, infiltrating monocytes and reduced PGE2 
expression in response to injection of saline or VZV antigens. This results in significant 
improvement of VZV-specific cutaneous T cell responses (Figure 8).  
Ageing leads to the accumulation of senescent cells in many tissues including the skin16, 18. 
Therefore the recruitment of inflammatory monocytes by senescent fibroblasts may also 
contribute to age-related decreased immune responses in other organs. The significant 
correlation between the number of senescent dermal fibroblasts and the extent of CD14+ 
monocyte infiltration indirectly supports the interaction between these cells. Although the 
abundance of senescent cells increases in the skin during ageing16, 17, 18, there is no overt 
expression of inflammatory mediators in un-manipulated skin of old subjects12. This suggests 
that at the steady state, the propensity to mount an inflammatory SASP response is inhibited 
by the increased numbers of Foxp3+ T regulatory cells (Tregs) and PD-1 expressing TRM 
cells observed in the skin of older people10, 12. Thus, the breakdown of homeostasis induced 
by tissue injury may override pre-existing inhibitory processes.  
PGE2 has disparate roles in immune responses as it has been shown to be pro-inflammatory 
(causing oedema formation and pain) as well as contributing to resolution of inflammation22. 
PGE2 can also suppress CD8+ T cells and may delay viral clearance24. Here we show that 
PGE2 inhibits CD4+ T cell and TRM proliferation in vitro thus confirming previous data 25. 
Furthermore, PGE2 has been shown to induce the expansion and increase the function of 
Foxp3+ Tregs26, 27 which may explain why these cells increases in the skin during ageing10, 28. 
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In addition, PGE2 may promote immunosuppression by increasing expression of the anti-
inflammatory cytokine IL-10 by mononuclear phagocytes29, 30. PGE2 can also have negative 
effects on DCs31. As CD11c+ DCs increase in the skin post-Losmapimod treatment, we 
cannot rule out that PGE2 may also have an inhibitory effect on DCs in the skin. 
We have confirmed previous observations that monocytes can inhibit antigen-specific 
responses32, 33. This is may be relevant for the Sars-Cov-2 pandemic which 
disproportionately affects older subjects34, since inflammatory monocytes have been found 
in the lungs of patients with severe COVID-19 disease35 and these cells may inhibit the 
function of virus-specific T cells, as described above.  
Excessive inflammation has been shown to inhibit antigen-specific immunity36 and reduce 
vaccination efficacy in many different contexts37, 38, 39. In addition to p38-MAPK inhibition, 
other drugs such as mTOR inhibitors, have been used to enhance immunity after vaccination 
in older individuals40. Furthermore, COX2 inhibitors have shown promise at improving DC-
based vaccine efficacy in mouse models of cancer41. The data presented here suggests that 
COX2 inhibitors which are routinely used in other inflammatory conditions could be used to 
improve immunity in older people. Thus, the inhibition of age associate inflammation in older 
subjects may be a promising approach for enhancing immunity to infection, cancer therapy 
and vaccination during ageing.  
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Figure 1: Recruitment of monocytes to sites of injection in the skin 
A, Schematic of visits for blood and skin sampling by old (>65 years) and young (<40 years) donors taking part in this study. B, representative 
image of a skin section stained with DAPI (white), CCR2 (red) and CD14 (blue), pink arrows indicate CD14 and CCR2 co-staining and blue 




 cells in C, saline-injected (n=9 young and 
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n=13 old biologically independent individuals). D, cumulative data showing the frequency of monocytes in normal (N) and Saline (6 hours; S6) 
in skin biopsies collected from young (white; n=6) and old (grey; n=5) individuals as assessed by flow cytometry. Cells were identified as 
mononuclear phagocytes if they were CD45
+
















 cells in VZV-injected skin a (n=5 Young and n=5 old biologically independent individuals) as compared to normal skin. F, 
Correlation between delta change in number of CD14
+
 cells in the skin after saline injection as compared to normal skin in relation to their VZV 
clinical response. Old donors are in black filled circles (VZV score 0-3; n=13), Old responders VZV clinical score ≥4; n=6) and young donors 
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Figure 2: Monocyte 
chemoattractant expression 
after saline injection in the 
skin  
A, representative image of 
normal and saline injected skin 
stained with CD31 (green) and 
CD62E (red) and B, 




endothelial loops expressing 
CD62E in young  (white; n=6) 
and old (grey; n=12). C, heat 
map showing expression of monocyte chemokines in normal then saline injected skin of young and old donors and D, cumulative data showing 
number of CCL2
+
 cells in young (white n=7) and old donors (grey; n=9) and E, representative image, arrows indicate double positive cells and F, 




 cells in normal and saline injected old skin (n=10). G, representative image showing DAPI 













 cells (n=10). I, correlation between the number of senescent fibroblast in normal skin (defined as being Telomere associated  
DNA damage foci [TAF] positive;) and the change in CD14
+
 monocytes after saline injection in old (black circles; n=3), old responders (red circles; 
n=2) and young (open squares; n=8) B, D, F and H, assessed with a paired t-test and I, assessed by a Spearmans rank correlation.  
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A, Heatmap showing the expression of genes associated with 
inhibitory mechanisms in normal and saline injected of old and 
young donors B, representative staining of DAPI (white), COX2 
(red) and CD14 (blue) in normal and saline injected skin and C, 





 cells in normal and saline injected skin 
(n=9). E, Monocytes were negatively isolated from the 
peripheral blood and cultured with and without LPS for 3 hours 
then subsequently co-cultured with autologous T cells (pre-
labelled with CellTrace Violet) that were activated with plate-
bound CD3 and IL-2, proliferation was assessed at day 4. A 
representative flow plot of CellTrace violet dilution in CD4
+
 T 
cells co-cultured with unstimulated and stimulated monocytes is 
shown in E and F, cumulative data showing percent of cells 
divided (n=10). A similar co-culture experiment was performed 
in the presence or absence of the COX2 inhibitor NS-398 (n=11) 
G, and H, or the EP4 receptor inhibitor MF498 (n=5) I, and J,. 
Control is unstimulated monocytes co-cultured with T cells in the 
presence of drug. Each data point within each figure is a biologically independent experiment. F, shown as mean ± SEM. In C,D, F, H and J 
analysed with a paired t-test.  
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 cell proliferation. 
A, representative staining of CD4 of eight independent donors 





 cells which co-express EP4. B, representative 




 cells and CD14
+
 
monocytes (blue) and C, cumulative data showing distance of 
CD14
+
 monocytes from T
RM
 in normal and saline injected skin 
from older adults (n=7). Monocytes were negatively isolated from 
the peripheral blood and cultured with and without LPS  for 3 
hours then subsequently co-cultured with skin T
RM
 cells (pre-
labelled with CellTrace Violet), which were collected from suction 
blisters (representative image in D) then activated with  plate-
bound CD3 and IL-2 and proliferation was assessed at day 4. E, 
representative flow plot of CellTrace violet dilution in T
RM
 cells co-
cultured with unstimulated (red line) or stimulated (blue line) 




  proliferation in the 
presence of stimulated or unstimulated monocytes, assessed at 
day 4 (n=4). C, and F, were analysed with a paired t-test.  
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Figure 5: Reduced inflammatory monocyte recruitment to the 
skin by Losmapimod pre-treatment 
A, Losmapimod clinical study diagram. Black arrows indicate study 
visits, red arrows indicate blood samples collected and blue arrows 
indicate skin biopsies taken. B, Colour coding of the clinical 
response of each individual after VZV challenge both before and 
after Losmapimod pre-treatment (pink/brown). Further colour 
coding was introduced to identify the extent of improvement where 
dark green identifies the biggest improvement and white shows no 
improvement in the skin. C, This coding was used in conjunction 
with the transcriptomic signatures in normal and saline injected 
skin before and after Losmapimod treatment. The top 30 genes 
upregulated in saline injected skin as compared to normal skin 
before pre- Losmapimod. D, Fold change of CCL2
+
 cells (n=7 





express p16 in saline injected pre- and post-Losmapimod 
treatment (n=7 biologically independent individuals). F, fold change 
CD14
+
 cell in the skin in response to saline injection (n=9 
biologically independent individuals) and G, number of CD14
+
 
monocytes in VZV injected skin (6 hours after injection; n=5 
biologically independent individuals) pre- and post-Losmapimod 
treatment. Significance in D-G assessed using a paired t-test.  
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Figure 6: Losmapimod restores T cell function by 
inhibiting monocyte COX2 and PGE
2
 production  
Monocytes were negatively isolated from the peripheral 
blood and cultured with and without LPS and in the 
presence or absence of Losmapimod for 3 hours, pellets 
were collected and western blot performed A, 
representative blot of phospho-p38 MAP Kinase (p-p38), 
total p38 MAP Kinase (p38), COX2 and GAPDH, full 
scans can be seen as source data fig.6. B, cumulative 
data of COX2 expression  assessed by western blot 
relative to GAPDH (n=3) and C, Prostaglandin E2 
(PGE
2
) production (n=6). Monocytes were negatively 
isolated from the peripheral blood and stimulated with 
LPS (blue) and without LPS (red) or with LPS in the presence of Losmapimod (white) for 3 hours then subsequently co-cultured with autologous 
T cells (pre-labelled with CellTrace Violet) in the presence of plate-bound CD3 and IL-2 proliferation was assessed at day 4. D, A representative 
flow plot of CellTrace violet dilution in CD4+ T cells co-cultured with unstimulated monocytes in the presence of Losmapimod (control; red) or 
stimulated monocytes (red) or stimulated monocytes in the presence of Losmapimod (black), and E, cumulative data showing percent of cells 




 cells between normal and saline injected skin before and after Losmapimod treatment 
(n=8). B, and C, shown as mean ± SEM and analysed by a one-way ANOVA with Tukey’s multiple comparison test and E, and F, analysed with 
a Wilcoxon matched-pairs signed rank test  
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Figure 7: Losmapimod 
treatment increases VZV 
induced T cell responses in the 
skin 
A, VZV clinical score and B, 
serum CRP concentrations in all 
donors pre- and post-
Losmapimod treatment (n=42). 
Representative images of CD11c 
(blue) and Ki67 (green) and  C, 
CD4 (red) or D, CD8 (red) 
staining at 7 days after VZV 
challenge pre- and post- 
Losmapimod. Cumulative data of 
E, CD4
+












 and I, CD11c
+
 staining 
after VZV challenge in 
responders pre- and post-
Losmapimod. Six hours (6h; n=5), 48 hours (48h; n=4) and Day 7 (n=7). E-I shown as mean + SEM and analysed by a wilcoxon-matched pairs 
test and   
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Figure 8: Schematic model of monocyte inhibition of cutaneous immunity in older adults 
In older adults the mild damage induced by injection (of air, saline or VZV) results in production of CCL2 from senescent fibroblasts and 
recruitment of monocytes into the skin 6 hours post injection. The recruited monocytes inhibit TRM proliferation via upregulation of COX2 and 
subsequent production of the lipid mediator Prostaglandin E2 (PGE2). The treatment of older adults with the p38 MAPK inhibitor, Losmapimod, 
results in reduced CCL2 production from the senescent fibroblasts and reduced monocyte infiltration. In addition, p38 MAPK is upstream of 
COX2 signalling, therefore the treatment with Losmapimod also inhibits COX2 upregulation and reduced PGE2 production. This significantly 
increases the T cell response to VZV in the skin of older subjects 
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Extended Data Figure 1: 
No gender difference 
observed in older adults 
in response to saline or 
Losmapimod. 
A, cumulative data showing 
the number of CD14+ and 
frequency of CCR2+ CD14+ 
cells in females (pink; n=8) 
and males (blue; n=5). B, Change in clinical score after Losmapimod treatment in female (pink; n=23) and male (blue; n=19), line indicates 
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Extended Data Figure 2: Flow cytometric analysis of dendritic cell populations in normal and saline injected skin. 
A, Normal and Saline-injected skin were digested overnight and assessed the following day by multiparametric flow cytometry. CD45+ cells 
were identified, followed by two singlet gates, subsequently cells that were CD3, CD56, CD19, CD20 Zombie Green (Lineage) negative and 
HLA-DR+ were selected, CD14-CD16-CD11c+ cells were assumed to be dendritic cells. Within the CD11c+ population CD1c and CD141 
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expression was assessed. Representative staining from Normal and Saline injected (6 hours) skin collected from an older adult is shown. 
Gating is based upon FMO controls from matched blood sample. Cumulative flow cytometry data of B, CD11c+, C,  CD141+ and D, CD1c+ 
dendritic cells (young n=5; old n=6 biologically independent individuals). Data analysed by paired t test and no significance was found. 
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Extended Data Figure 3: No change in CD66b+ neutrophil numbers after saline-injection 
A, representative staining of saline-injected skin stained for DAPI (white), and CD66b (purple) and B, cumulative data showing the number of 
CD66b+ cells in normal and saline-injected young (white) and old (grey) (young n=4; old n=6 biologically independent individuals). Data 
assessed by paired t-test and no significance was found. 
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 Extended Data Figure 4: Baseline and 24 hours post-saline injection monocyte 
populations. 
A, Comparison of baseline monocyte populations in the skin of based on CD14+ and 
CCR2+ expression in young (n=22 biologically independent individuals) and old (n=24 
biologically independent individuals) individuals . B, Normal and Saline-injected skin were 
collected 24 hours post-injection from n=5 young (average age 30 years; 3 male and 2 
females) and n=7 old (average age 70 years; 2 males and 5 females). Samples were 
digested overnight and assessed the following day by multiparametric flow cytometry. Cells 
that were CD45+HLA-DR+and  CD3, CD56, CD19 and CD20 negative were considered to 
be mononuclear phagocytes, within this population CD14+ monocytes were assessed. C, 
Cumulative delta change in number of CD14+ or CCR2+CD14+ cells in air-injected skin 
from young (n=6 biologically independent individuals) and old (n=5 biologically independent 
individuals) volunteers as compared to normal skin. A, and C, shown as mean ± SEM. A 
and C assessed by an unpaired t test and B, assessed by paired t-test. 
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Extended Data Figure 5: Flow cytometric analysis of monocyte and neutrophil populations in normal and saline injected skin  
A, Normal and Saline-injected skin were digested overnight and assessed the following day by multiparametric flow cytometry. CD45+ cells 
were identified, followed by two singlet gates, subsequently cells that were CD3, CD56, CD19, CD20 Zombie Green (Lineage) negative and 
HLA-DR+ were considered to be mononuclear phagocytes, within this population CD14+CCR2+ and CD14+CD16+ monocytes and 
CD16+HLA-DR- neutrophils were assessed. Representative staining from Normal and Saline injected (6 hours) skin collected from an older 
adult is shown. Gating is based upon FMO controls from matched blood sample. Normal and Saline-injected young (white) and old (grey) skin 
was assessed by flow cytometry and B, cumulative data of the frequency of CD16+HLA-DR- neutrophils and C, cumulative frequency of the 
number of CCR2+CD14- cells (young n=7; old n=6). Unbiased representations of multi-parameter flow cytometry data were generated using 
the t-distributed stochastic neighbor embedding (tsne) algorithmt-SNE. Tsne is a non-linear dimensionality reduction method that optimally 
places cells with similar expression levels near to each other and cells with dissimilar expression levels further apart. D, tsne cluster plots of 
young and old normal and saline injected skin and E, heatmap of clusters in normal and saline-injected skin of young (Y) and old (O) adults and 
F, marker expression plots. Data analysed by paired t test and no significance was found. 
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Extended Data Figure 6: Minimal Ki67+ macrophages are observed in saline-injected skin 
A, representative staining of normal and saline-injected skin stained for DAPI (white), Ki67 (green), and CD163 (blue) and B, cumulative data 
showing the number of CD163+Ki67+ and C, frequency of Ki67+ CD163+ cells in young (white; n=4) and old (grey n=5). Data assessed by 
paired t-test and no significance was found. 
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Extended Data Figure 7: Representative staining of monocyte chemoattractant expression after saline injection in the skin 
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A, representative images of saline-injected old skin stained with DAPI (white), CCL2 (green) and CD14 (blue) and B, cumulative data showing 
the number of CD14+CCL2+ cells in normal and saline injected skin of young (white n=7 biologically independent individuals) and old skin 
(black n=8 biologically independent individuals). C, representative staining of saline-injected old skin of DAPI (white) CCL2 (green) and FSP1 
(red) and D, representative images of normal and saline-injected old skin stained with DAPI (white), CCL2 (green), p16 (red) and FSP1 (blue). 
Arrows indicate double positive. E, cumulative data showing the frequency of CCL2+FSP-1+ that express p16+ in old normal and saline-
injected skin (n=7 biologically independent individuals).  B, and E, assessed with a paired t-test and no significance was found. 
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Extended Data Figure 8: Representative TAF staining 
Representative images of saline-injected old skin stained with DAPI (white), Telomere probe (intranuclear; red), FSP-1 (cell surface; red), and 
yH2AX (green). 
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Extended Data Figure 9:  CD14 and COX2 
staining in normal and saline-injected older 
skin 
A, Representative images of old normal and 
saline-injected skin sections stained with DAPI 
(white), COX (red) and CD14 (blue). B,  cumulative 
data showing the number of CD14-COX2+ cells in 
normal and saline-injected old skin (n= 8 
biologically independent individuals). 
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Extended Data Figure 10: Losmapimod reduces 
the expression of monocyte chemokines 
 A, top six genes upregulated in saline injected as 
compared to normal skin, when ranking by average 
fold change for genes significantly upregulated (adj.p 
< 0.05) before and after Losmapimod pre-treatment 
(box shown as median, ± interquartile range and 
error bars of 1.5*IQR). B, Saline-specific gene 
expression pre and post-Losmapimod and C, 
correlation between change in saline-specific gene 
expression or D, change in CCL2 gene expression 
and change in clinical score and  pre- and post-
Losampimod. E, heat map of gene expression of 
monocyte chemokines in normal and saline injected 
skin pre- and post-Losmapimod. F, Senescent fibroblasts were cultured with Losmapimod (3μM) for 3 or 24 hours, and supernatants were 
collected. CCL2 concentrations were assessed by cytometric bead array (n=6). For A-D n=15 biologically independent individuals. B and F 
assessed by paired t test and C and D assessed by Spearman’s rank correlation test. * = p<0.05** = p<0.01 *** = p<0.001
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Materials and Methods: 
Study design:  
The investigation of healthy young (under 40 yrs) and old subjects (65 yrs and over) was 
approved by the Ethics Committee Queen’s Square (London) and by institutional review 
board (UCL R&D). Individuals with history of neoplasia, immunosuppressive disorders or 
inflammatory skin disorders were excluded as described in detail elsewhere9 (see 
Supplementary Table 1 for donor characteristics). In brief, we excluded individuals with co-
morbidities that are associated with significant internal organ or immune dysfunction 
including heart failure, severe COPD, diabetes mellitus and rheumatoid arthritis and 
individuals on immunosuppressive regimes for the treatment of autoimmune or chronic 
inflammatory diseases (e.g. oral glucocorticoids, methotrexate, azathioprine and 
cyclosporin). In addition, individuals with history of liver disease or elevated liver 
transaminases (>1.5 times the upper limit of normal), or who had abnormal ECG. All 
volunteers provided written informed consent and study procedures were performed in 
accordance with the principles of the declaration of Helsinki. No statistical methods were 
used to pre-determine sample sizes of this section of our data, but our sample sizes are 
similar to those reported in previous publications 8, 9, 12, 28. 
For the study involving Losmapimod, we recruited 42 healthy older adults (>65 years); 19 
males and 23 females with a mean age of 70.7 years old (95% CI 69-72.3 years old). A 
power calculation was performed to establish effect on change in clinical score, and we 
assumed an alpha level of 0.05 (2-sided) and a power of 0.90 was considered desirable. 
VZV skin test was performed and biopsies collected at different time points as described9. 
Only Caucasian European individuals were included in the study and Any individual with a 
clinical score >3 was excluded from the study as described previously9.  Two to three 
months after the first VZV skin challenge the same volunteers received 15 mg Losmapimod 
(GW856553) twice a day for 4 days (provided by GlaxoSmithKline [GSK] under a Medical 
Research Council Industrial Collaboration Agreement). We have found previously that the 
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first VZV challenge did not significantly boost the response to re-challenge of the same 
individuals after 2-3 months9. Losmapimod 15 mg twice a day dose used in this study was 
chosen on the basis of the PK, PD and safety profiles of Losmapimod observed in GSK 
Phase I and II studies42. These individuals were then re-challenged with VZV skin antigen 
and biopsies were collected at the same timepoints as before Losmapimod treatment. 
Clinical scores after VZV injection were performed by two independent researchers and an 
average reading was recorded. Serum CRP levels were measured with a high sensitivity 
assay (pre- and post-Losmapimod). No adverse side effects were observed in our study 
group in response Losmapimod pre-treatment for 4 days.  
We were advised by the UK’s Medicines and Healthcare products Regulatory Agency 
(MHRA) that it was not a Clinical Trial of an Investigational Medicinal Product (IMP) as 
defined by the EU Directive 2001/20/EC. As this experimental medicine study was designed 
to test a hypothesis in humans in vivo and not to determine the therapeutic outcome or 
efficacy of the drug Losmapimod for patient benefit. Therefore no randomisation was 
performed. The life sciences reporting summary of this work can be found in the 
supplementary information. 
 
Skin tests and punch biopsy:  
VZV antigen (BIKEN, The Research Foundation for Microbial Diseases of Osaka University, 
Japan) or 0.9% saline solution or an equal volume of air was injected intradermally into sun 
unexposed skin of the medial proximal volar forearm as per manufacturer’s instructions. 
Induration, palpability and the change in erythema from baseline were measured and scored 
on day 2 or 3 as described previously11. A clinical score (range 0-10) based on the 
summation of these parameters was then calculated. Donor characteristics can be found in 
Supplementary Table 1. 
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Two punch biopsies (5 mm diameter) were collected from normal (unmanipulated skin) and 
either saline injected or VZV injected site (at time-points as indicated). Biopsies were frozen 
in OCT (optimal cutting temperature compound; Bright Instrument Company Ltd). 6μm 




Sections were stained with optimal dilutions of primary antibodies and followed by relevant 
secondary antibody conjugated to various fluorochromes as described (Supplementary 
Table 2). Skin sections were imaged on the AxioScan Z1 slide scanner and analysed using 
Zen Blue (Zeiss) For normal and 6 hour injected skin and endothelium counts, total cells in 
the upper dermis were counted and numbers of cells per mm2 were calculated. Images were 
taken from the upper dermis, an example of which is shown in Figure 1. For VZV injected 
skin (days 2-7) the number of cells in five of the largest perivascular infiltrates present in the 
upper and mid dermis were selected for analysis and an average was calculated as 
described previously10. Staining for telomere-associated ɣH2AX foci (TAF) were carried out 
as described previously16. Counting was performed manually, the data was blinded to the 
assessor to avoid any bias and where multiple skin sections from one sample were 
assessed the average of the counts was used. 
 
Skin Biopsy digestion for flow cytometric analysis:  
Skin biopsies (5 mm) were taken from normal and saline injected skin (6 or 24-hours post-
injection) and disaggregated by overnight incubation (37oC) in either 0.8 mg/ml collagenase 
IV (Sigma Aldrich) with 20% FCS or a whole skin digestion kit from Miltenyi Biotec. Single 
cell suspensions were obtained and subsequently stained with the cell surface antibodies as 
listed in Supplementary Table 3. Samples were assessed by flow cytometric analysis on a 
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BD Fortessa using FACSDIVA software, and subsequently analysed using FlowJo Version X 
(BD Biosciences). 
Unbiased representations of multi-parameter flow cytometry data were generated using the 
t-distributed stochastic neighbour embedding (tsne) algorithm. The R package “Rtsne” 
available on CRAN (github.com/jkrijthe/Rtsne) was used to perform the Barnes Hut 
implementation of t-SNE on flow cytometry data. FlowJo software was used to export events 
of interest (in fcs format) for each sample. After using the Bioconductor “flowCore” R 
package to import fcs file data and the Logicle transform to scale the data similarly to that 
displayed in FlowJo, 3000 HLA-DR+ events from each samples analysed in parallel were 
merged and the relevant fluorescent parameters were used. 
 
RNAseq analysis of skin:  
Three 3 mm punch biopsies were collected from each volunteer: VZV injection site at 48 
hours post-injection, saline injection site at 6 hours post-injection and normal (un-injected) 
skin as a control. Biopsies were immediately frozen in RNAlater. Frozen tissue was 
homogenized, and total RNA was extracted from bulk tissue homogenates using RNeasy 
Mini Kit (Qiagen). Library preparation for RNAseq was performed using the Kappa 
Hyperprep kit (Roche Diagnostics) and sequencing was performed by the Pathogens 
Genomic Unit (UCL) on the Illumina Nextseq 500 (Illumina) using the NextSeq 500/550 High 
Output 75 cycle kit (Illumina) according to manufacturers’ instructions, giving 15-20 million 
41bp paired end reads per sample. Reads were aligned to Genome Reference Consortium 
Human Build 38 (GRCh38) using Hisat243. Samtools was used to select for reads with paired 
mates. Transcript assembly was carried out using StringTie44, with gene-level Fragments per 
Kilobase of transcript per Million mapped read (FPKM) generated using Ballgown45. The 
RNAseq data has been deposited on Gene Expression Omnibus (Accession Number: 
GSE130633).  
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Statistical comparisons were made on gene count estimates generated by StringTie. Genes 
with low expression (<1 count per million mapped reads in 95% of the samples) or short 
transcript lengths (<200 nucleotides for the longest transcript) were removed. The count 
matrix was normalised using the TMM method in edgeR (version 3.22.5)46, followed by 
contrast fit with voom in limma (version 3.36.5)47, treating the subject ID as a blocking 
variable. Statistically significant differentially expressed genes were with an adjusted p-value 
of less than 0.05 and expression change of greater than 2-fold up or down, were considered 
to be statistically significant.  
Gene correlation networks (GCN) were constructed and visualised using Graphia 
Professional (Kajeka Ltd, version 2.1; , https://graphia.app/). Genes without a known HUGO 
gene nomenclature, or with expression < 1 FPKM for all samples, were removed from the 
co-expression network analysis. The Markov Cluster Algorithm (MCL) was used to define the 
network clusters using an inflation value of 2.2. Saline-specific gene expression was 
generated using the average expression (FPKM) for genes that are significant in  
Pre-Losmapimod in saline-injected skin as compared to normal (Fold change>2 and 
p<0.05). RNAseq data that support the findings of this study have been deposited in NCBI 
Gene Expression Omnibus accession code GSE130633. 
 
Leukocyte isolation from peripheral blood: 
PBMC were isolated by density centrifugation using Ficoll-Paque (Amersham Biosciences). 
CD4+ T cells were purified by positive selection and monocytes were isolated by negative 
selection according to the manufacturer’s instructions (Miltenyi Biotec).  
 
Monocyte and T cells co-culture: 
Monocytes (1x106/ml) were cultured in the presence of LPS (1ng/ml) and/or NS-398 (1µM) 
at 37oC with 5% CO2. Monocytes were collected three hours post incubation and washed 
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once to remove residual LPS. These  cells  were pre-incubated with inhibitors NS-398 (1µM) 
or Losmapimod (3µM) where indicated. CD4+ T cells were labelled with CellTrace Violet 
(Invitrogen) according to the manufacturer’s instructions prior to culture. CD4+ T cells  and 
monocytes (unstimulated or LPS stimulated) were co-cultured at different ratios, in the 
presence of plate-bound CD3 (1µ/ml) and IL-2 (50IU/ml) and MF-498 (1µM) as indicated (at 
37oC with 5% CO2) for four days. 
For experiments involving co-culture of monocytes with skin TRM cells, two suction blisters 
were formed over uninjected skin, as described previously11. Cells were collected from the 
blister the following day and incubated on plastic for 3 hours, to remove mononuclear 
phagocytes. Cell suspensions (predominantly CD4+ T cells) were removed and labelled with 
CellTrace Violet and co-cultured with unstimulated or LPS stimulated monocytes as 
described above. 
 
T cell proliferation assessment: 
Samples were collected on day 4 post-culture and stained for the following: CD3 (UCHT1), 
CD4 (RPA-T4; BD Biosciences) and Zombie NIR™ Fixable Viability Kit (Biolegend). 
Samples were assessed by flow cytometric analysis on a BD Fortessa using FACSDIVA 
software, and subsequently analysed using FlowJo Version X (BD Biosciences). 
 
Western Blot analysis: 
Cell pellets were harvested and lysed with RIPA buffer (Sigma-Aldrich) supplemented with 
protease and phosphatase inhibitors (Cell Signalling) for 30 min on ice. Cell lysates were 
diluted in SDS sample buffer with reducing agent (NuPage, Life Technologies) and boiled for 
5 min at 95 °C. Samples were separated by protein electrophoresis at 120 V for 2 h using 
10% Bis-Tris pre-cast gels (NuPage) and transferred overnight at 4°C onto Hybond-P PVDF 
membranes (GE Healthcare). After blocking in ECL blocking agent (GE Healthcare), 
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membranes were probed with primary antibodies overnight at 4°C. Primary antibodies used 
were COX2 (ab15191; Abcam), phospho-p38 MAPK (T180/Y182; 9211), and p38 MAP 
Kinase (9212), GAPDH (2118; Cell Signalling). The membrane was washed and incubated 
with HRP-conjugated secondary antibodies (GE Healthcare, 1:4000) for 1 h at room 
temperature. Antibodies were detected using the ECL detection kit (GE Healthcare). Prior to 
re-probing with different antibodies, membranes were stripped at room temperature with 
agitation using Restore stripping buffer (Thermo Scientific). Protein bands were quantified 
using ImageJ software. The integrated density of each band was normalised to GAPDH 
using the gel analysis function of ImageJ. 
 
Dermal Fibroblast isolation and culture: 
Dermal fibroblasts were isolated and cultured as described previously16. Senescence was 
induced in these cells by exposure to X-ray radiation at a total dose of 10Gy at a rate of 
5Gy/min. Irradiated cells were cultured for a further 10-28 days to allow for senescence to 
develop. Senescence was confirmed by staining for SAβ-galactosidase (Cell signalling). 
Non-senescent (early passage number 4-10) and senescent fibroblasts were cultured in a 
48-well plate at 20 × 104 cells per well in the presence of absence of Losmapimod (3µM), 
and supernatants were collected at 3 and 24 hours. 
 
Assessment of supernatants: 
Cytokine concentration in culture supernatants were assessed by cytometric bead array 
(CBA) according to the manufacturer's protocol. Samples were analysed using a BD Verse 
flow cytometer (BD Biosciences). The lower limit of detection for each analyte was 1.5pg/mL. 
For assessment of PGE2 production from monocyte cultures with a Prostaglandin E₂ Direct 
Biotrak Assay was used according to the manufacturers protocol (Fisher scientific). 
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Statistics:  
Statistical analysis was performed using GraphPad Prism version 8.00 (GraphPad 
Software). Data was assessed for normality and the subsequent appropriate statistical two-
sided statistical test was performed as indicated in the legend of each figure. 
 
Code availability statement: Scripts used in the RNA-seq analysis can be found on the 
GitHub repository at https://github.com/barbarashih/arise_losmapimod 
Data availability statement: RNAseq data that support the findings of this work, can be 
found RNAseq data that support the findings of this study have been deposited in NCBI 
Gene Expression Omnibus, accession code GSE130633. The rest of the data that support 
the findings of this study are available as source data. 
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